Effects of LY2603618 on the cytotoxicities of etoposide, doxorubicin, or cisplatin against high-risk neuroblastoma cell lines.

<p><b>Note:</b> SK-N-SH and SK-N-BE(2) cells were treated with variable concentrations of etoposide, doxorubicin or cisplatin for 48 h in the absence or presence of 4 or 8 µM LY2603618 administered simultaneously. Viable cells were measured by MTT assays and the extent and direction of antitumor interactions between LY2603618 and etoposide, doxorubicin, or cisplatin were determined by using the CompuSyn software. The numbers in the brackets represent for the combination index (CI) values, where CI<1, CI = 1, and CI>1 indicate synergistic, additive, and antagonistic effects, respectively. The data are presented as means±standard errors from at least 3 independent experiments.